Centessa Pharmaceuticals plc (CNTA) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Centessa Pharmaceuticals plc ("Centessa" or "the Company") (NASDAQ: CNTA). Investors who purchased Centessa securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Centessa and certain of its officers and/or directors have violated federal securities laws.

On or around May 27, 2021, Centessa conducted its initial public offering (“IPO”), selling 16.5 American Depositary Shares (“ADSs”) priced at $20.00 per share.  Then, on June 2, 2022, Centessa issued a press release “announc[ing] that it has made the strategic decision to discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) including both the Phase 3 ACTION Study and the open-label ALERT Study.”  Centessa specified that “[t]he decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD, and the incremental development challenges and associated costs, following a recent observation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations in one subject in the ALERT Study.”  On this news, Centessa’s ADS price fell sharply during intraday trading on June 2, 2022.


If you are aware of any facts relating to this investigation or purchased Centessa shares you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 


Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.